Scientific Terms Feb 1, 2023 Novartis' Oncology Drugs See Solid Growth in Q4 2022 Premium Feb 1, 2023 Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Feb 1, 2023 Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Jan 31, 2023 Pfizer Q4 Oncology Revenues Fall 7 Percent Premium Jan 31, 2023 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers Jan 31, 2023 Aptose Biosciences Begins Expansion Trial of Tuspetinib in TP53, FLT3-Mutant AML Jan 31, 2023 Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering Jan 30, 2023 C4 Therapeutics Begins Phase I/II Trial of Protein Degrader in BRAF V600-Mutant Solid Tumors Jan 30, 2023 Daiichi Sankyo, AstraZeneca Begin Phase III Trial of TROP2 Inhibitor, Keytruda in NSCLC Jan 30, 2023 Menarini's Orserdu, Guardant's ctDNA CDx Net FDA Approval for ESR1-Mutated Breast Cancer Patients Jan 27, 2023 Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial Jan 26, 2023 Circulating Tumor DNA Testing Informs Best Second-Line Treatment for Gastrointestinal Stromal Tumors Premium Jan 26, 2023 NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients Jan 26, 2023 Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer Jan 25, 2023 Indivumed Sells Biospecimens Service Unit to CRO Crown Bioscience Jan 25, 2023 Verastem Oncology Plans for FDA Submission of Avutometinib-Defactinib Combo in Ovarian Cancer Jan 24, 2023 New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions Premium Jan 24, 2023 Geneseeq Nabs CE Marks for Residual Disease and Cancer Early Detection Tests Jan 24, 2023 Ibex Inks Deal With AstraZeneca, Daiichi Sankyo to Develop AI-Based HER2 Scoring Jan 24, 2023 ImmPact Bio to Begin Phase I/II Trial of Bispecific CAR T-Cell Therapy in Aggressive Lymphoma Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers